ADC Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Oaktree Fund Administration, LLC(5.19%),Oaktree Capital Holdings, LLC(5.19%), etc.
May 3 21:37 ET
ADC Therapeutics | DEF 14A: Definitive information statements
Apr 26 16:34 ET
ADC Therapeutics | DEFA14A: Others
Apr 26 16:26 ET
ADC Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-A.T. Holdings II Sarl(2.7%),C.T. Phinco Sarl(2.7%), etc.
Apr 25 16:16 ET
ADC Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Apr 16 16:22 ET
ADC Therapeutics | 8-K: Current report
Apr 9 16:12 ET
ADC Therapeutics | 424B3: Prospectus
Mar 15 16:18 ET
ADC Therapeutics | 424B3: Prospectus
Mar 15 16:17 ET
ADC Therapeutics | EFFECT: Others
Mar 15 06:35 ET
ADC Therapeutics | EFFECT: Others
Mar 15 06:25 ET
ADC Therapeutics | EFFECT: Others
Mar 15 06:20 ET
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Mar 13 16:23 ET
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Mar 13 16:21 ET
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Mar 13 16:20 ET
ADC Therapeutics | ARS: Annual Report to Security Holders
Mar 13 15:24 ET
ADC Therapeutics | 10-K: Annual report
Mar 13 12:28 ET
ADC Therapeutics | 8-K: ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Mar 13 07:43 ET
ADC Therapeutics | 8-K: Current report
Mar 5 09:17 ET
ADC Therapeutics | 8-K: Current report
Feb 29 16:34 ET
ADC Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Redmile Group, LLC(18.8%),Jeremy C. Green(18.8%), etc.
Feb 14 16:29 ET
No Data
No Data